

mgc pharma



Improving Lives
With Innovative Medicine

MGC Pharma is paving the way in the Life Science Sector with innovative medicines for under-treated medical conditions

“Our vision is to have a global impact on under-treated medical conditions and diseases.

“Wielding the power of plant-inspired medicines in novel combinations by using innovative medical technologies to harness knowledge and science towards achieving our “Nature to Medicine” strategy and creating the next-generation of medications.”


Roby Zomer
Co-Founder, Director & CEO

Established Pharma Platform

- ❖ Plant-inspired ingredients and pharmaceutical formulations
- ❖ Integrated global research hub
- ❖ Experienced pharma & research team
- ❖ Corporate team with extensive pharmaceutical expertise
- ❖ Malta GMP pharma-standard auto manufacturing facility
- ❖ Advance Clinical program with innovative formulation
- ❖ Acquisition & integration of ZAM app
- ❖ ESG focussed team, with more than 60% women

MGC Pharma: a Unique Market Proposition

The rapidly expanding market for plant-inspired medicines provides new opportunities for growth.



* ReportLinker. (2022, March 4). Pharmaceuticals Global Market Report 2022. Globalnewswire.com.

* ReportLinker. (2022, June 7). Herbal Medicine Market Research Report by Product, Form, Source, Type of Medicinal Plant, Indication, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19. Globalnewswire.com

Global Footprint

United Kingdom

Corporate HQ & LSE Listing

Slovenia

R&D Centre & GMP IMP facility

Malta

Cutting Edge
GMP* Facility

Israel

Clinical Research Hub

Australia

ASX Listing

Our Distributors network

AMC HOLDINGS, INC. USA

 Sciensus EU, EEA & MENA

 Lenis Balkan & Baltics

 OnixCann CANNABIS MEDICINAL Brazil

Company Board and executive team

Highly qualified team with decades of relevant industry experience



Roby Zomer
Managing Director &
CEO



Brett Mitchell
Non-Executive
Chairman



Dr. Stephen Parker
Senior Independent
Director & Chair of
Board Committees



Nativ Segev
Non-Executive
Director



Dr. Ross Walker
Non-Executive
Director



Evan Hayes
Non-Executive
Director



David Lim
Company Secretary



Yifat Steuer
Chief Operational
Officer



Angela-Marie Graham
Chief Financial Officer



Robert Clements
Chief Commercial
Officer



Itay Nissim
Chief Manufacturing
and Supply Chain
Officer



Dr. Nadya Lisodover
Chief Medical Officer



Amir Polak
Chief Pharmaceutical
Development Officer



Yair Tal
Chief Information
Security Officer

For personal use only

Company Medical Advisory Board

For personal use only



Professor David Neubauer

As Head of the Department of Child, Adolescent, and Developmental Neurology at University Children's Hospital, Ljubljana, Dr. Neubauer is widely published and respected and has dealt with children and adolescents in Neurological contexts for more than thirty years.



Professor Uri Kramer

One of the few medical professionals in the world to have run full-scale epilepsy trials with Cannabis, Dr. Kramer brings a wealth of experience in various fields (Neurology, Paediatric Neurology, Adolescent Psychology & Child Development). Additionally, Professor Kramer is a Former president of the Israeli League Against Epilepsy, giving him unique insight into the daily struggles of the patients his research benefits.



Dr. Jonathan Gruenfeld

He is certified in Israel, with clinical experience at the MD Andersen Cancer Centre, [Prof]. Gruenfeld has spent the last twenty years focusing on Neuro-Oncology, focusing since 2010 on Cannabis as a treatment for oncological palliative care. Involved in licensing maintenance of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups, and developing treatment methodology.



Dr. Ross Walker

Dr. Walker is a well-known Australian health figure, the former host of a weekly radio program, and a prominent cardiologist specialising in echocardiography and preventative cardiology. Dr. Walker has published several books and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.



Dr. Nadya Lisodover

15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisodover is a regulatory expert and has been clinical adviser to public biotech companies and a range of incubator and acceleration including Furtux- a J&J Innovation and Takeda program.

Leaders in the pharma and the life sciences sector with unparalleled expertise

During the past 24 months the company has transformed into a Pharma company with:

- ❖ 3 drugs in clinical development
- ❖ 4 drugs in preclinical development
- ❖ Completion of two successful Phase II studies on CogniCann® and CimetrA®.
- ❖ Operational Research and Development site
- ❖ Construction and deployment completed of two Pharma-grade production sites (Malta GMP approved)
- ❖ Acquisition of AI Platform providing MGC Pharma with real-time information on large data, supporting doctors in the provision of more accurate treatment in a shorter time.
- ❖ CannEpil approved by the Irish Medical Cannabis Products Reimbursement Scheme (MCPRS) and obtaining full health insurance converge

Our flagship line of products are developed to fight the most demanding conditions.

CimetrA®



Investigational
Medicinal Product

Anti-Inflammatory

Phase IIb and Phase III

Market size estimated £30b¹

CannEpiL®



Investigational
Medicinal Product

Refractory Epilepsy

Phase IIb

Market size estimated £15b²

CogniCann®



Investigational
Medicinal Product

Dementia

Alzheimer's

Phase II

Market size estimated £15b³

IrniCann®



Investigational
Medicinal Product

Glioblastoma

Market size estimated £4b⁴

- <https://www.researchandmarkets.com/reports/5446184/coronavirus-covid-19-current-therapy-global>
- <https://www.biospace.com/article/epilepsy-therapeutics-market-worth-15-1-bn-by-2030-at-a-cagr-of-4-5-percent/>
- <https://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market>
- <https://www.grandviewresearch.com/industry-analysis/glioblastoma-multiforme-treatment-gbm-market/>

*Investigational Medicinal Products (IMP) are medicinal products designed and manufactured for clinical trials, and they are made available to patients via early access schemes (depending on territory).

Flagship Product – COVID-19 & Anti-Inflammatory

Anti-Inflammatory

CimetrA®

- IMP based on two active ingredients: Dry extracts of *Curcuma longa* and *Boswellia serrata*;
- Delivered via nanoparticle suspension, demonstrating the suppression of cytokine storm in COVID-19 patients;
- None of the treatment group patients in the on-going study have required additional oxygen, mechanical ventilation, or admission to intensive care**;
- Results from a Pre-clinical In-vitro study indicate wide-ranging application as an anti-inflammatory treatment through the modulation of the production of pro-inflammatory cytokines;
- One of the key findings of the current study was the effective blocking of the IL-32mRNA expression, the pro-inflammatory cytokine related to Rheumatoid Arthritis, Inflammatory bowel disease, Asthma, Psoriasis, and Chronic obstructive pulmonary disease;
- **IP Protected (IP Number – SIPO 26055)**

Phase IIb and Phase III



Lead product



Oromucosal spray

Pharmaceutical dosage form

Phase III started Q1 2023 IND (FDA) Q3 additional site for phase III H1 2024 completion of phase IIb



For personal use only

* Developed from our food supplement ArtemiC®.

**According to the interim analysis 2022

Flagship Product – Refractory Epilepsy

CannEpil®

- IMP based on two active ingredients: Cannabidiol and Delta-9-Tetrahydrocannabinol;
- Designed as a treatment for refractory epilepsy aka "Drug-Resistant" (DRA);
- Approximately 25% of people with epilepsy have a drug-resistant (DRA) form;
- The first legal medicinal cannabis product eligible for patients in Ireland and fully covered under Ireland's Primary Care Reimbursement Service as part of the country's medicinal Cannabis Access Program (MCAP);
- Available via prescription in selected territories through special access schemes;
- Safety Study results show that CannEpil® was found to be safe for post-treatment driving activities. Considered the gold standard of safety studies in psychoactive ingredients;
- **IP Protected (IP Number – SIPO 26056);**



Refractory Epilepsy

Phase IIb




Lead product


Oromucosal solution
Pharmaceutical dosage form

For personal use only

Flagship Product - Dementia and Alzheimer's

CogniCann®

- IMP is based on two active ingredients: Delta-9-Tetrahydrocannabinol and Cannabidiol.
- Designed as a treatment for the symptoms associated with Dementia and Alzheimer's.
- The safety and efficacy were assessed in a Phase II study in Australia;
- Patients in the Placebo group experienced a deterioration in their condition, compared with the stable neuropsychiatric profile of those patients in the treatment group with CogniCann®;
- Patients' aggressive behaviour improved by 13%, compared with the Placebo Group, which improved by 4%;
- This important finding indicates not only improvement in the health status of the patients but also the improved quality of life of the families and caregivers taking care of dementia patients;

Dementia

Alzheimer's

Phase II



Oromucosal spray


Pharmaceutical
dosage form

New Medical Product- Glioblastoma

IrniCann®

- IMP based on two active ingredients: Cannabidiol and Cannabigerol.
- The Glioblastoma pre-clinical research, conducted between 2019-2022, initially used a formulation that included THC (delta-9-tetrahydrocannabinol), which was later replaced with Cannabigerol (CBG), which has no known psychotropic effects.
- The study demonstrated that IrniCann® was cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis (or cell death).
- MGC Pharma is planning to undertake additional research to further demonstrate the formulation's efficacy as a treatment for Glioblastoma.

For personal use only



Glioblastoma

Pre-clinical




Capsules

Pharmaceutical dosage form

Research and Development – Product Pipeline

FDA & EMA registration



Market Access Network

For personal use only

USA: CimetrA®, CannEpil®, CogniCann®
- AMC

Brazil: CannEpil®, CogniCann®:
- ONIX

UK: CannEpil®:
- SCIENSUS RARE

Ireland: CannEpil®:
- PACELLI

Balkan & Baltics - CannEpil®:
- LENIS

EU & EEA: CannEpil® & CogniCann®:
- SCIENSUS RARE

MENA Counties:
CannEpil®, CogniCann®:
- SCIENSUS RARE


Integrated Research Hub

- MGC Pharma manages and runs all clinical trials in-house, in accordance with the European Medicines Agency, Federal Drug Administration, ICH Good Clinical Practice, and Israeli health regulations.
- MGC Pharma's CRO ('MediCaNL') delivers cost savings to the Company compared to third party services.
- MediCaNL currently has three clients (excluding MGC Pharma) which provide MGC Pharma additional revenue stream.
- MediCaNL is leading the clinical trials of CimetrA® and CannEpil®



Fully built GMP pharma standard manufacturing facility

- A formal EU GMP certification as a production facility is now expected to be formalised in early 2023.
- The company will have two, high-quality, EU GMP certified production facilities from which it will be able to manufacture and distribute its proprietary IMP products CimetrA®, CannEpil®, and CogniCann® across the EU, and globally







ZAM Medical Data App

Helping Doctors to give better treatment

- ZAM will enable patients to log their medical history and monitor medication use.
- The ZAM App will provide users with an in-depth understanding of their health and treatment progress through patient data collection.
- The Artificial Intelligence (AI) Algorithm will use data collected from the ZAM App, including results from academic and clinical studies, to predict potential conflicting side effects from multiple treatments.



Meta Medix (MGC Research) – Products Offering



- Ongoing organic growth of our supplements and medical-cannabis products worldwide
- Meta Medix Cumulative Sales have reached c.£2.4m (c.88k units) over the last 12 months

Key Milestones for 2023

- ❖ CimetrA® IND (FDA) submission
- ❖ Ramp up Sciensus Rare
- ❖ Commissioning the Malta facility
- ❖ Continue the development of CannEpil®
- ❖ Progress on CannEpil® Phase IIb
- ❖ Enrolment of additional users to ZAM



Thank you for your time

 info@mgcpharma.eu

 [@mgcpharmaceuticals](https://www.facebook.com/mgcpharmaceuticals)

 [@MGC_Pharma](https://twitter.com/MGC_Pharma)

 [MGC Pharmaceutical Ltd.](https://www.linkedin.com/company/mgc-pharmaceutical-ltd)

 mgcpharma.co.uk

Disclaimer

The information contained in this presentation and any accompanying oral presentation ("Presentation") is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, "MGC"). By accepting this Presentation, you agree to be bound by the following terms.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).

This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.

This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as "Relevant Persons"). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in MGC is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

No Liability

The information contained in this Presentation has been prepared in good faith by MGC, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including MGC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, MGC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of

or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

MGC, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects MGC's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify MGC for any loss or damage incurred as a result of your breach of this undertaking.